Switch to:
Also traded in: Brazil, France, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.27
ABBV's Cash to Debt is ranked lower than
83% of the 767 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.75 vs. ABBV: 0.27 )
Ranked among companies with meaningful Cash to Debt only.
ABBV' s Cash to Debt Range Over the Past 10 Years
Min: 0.27  Med: 0.65 Max: No Debt
Current: 0.27
Equity to Asset 0.09
ABBV's Equity to Asset is ranked lower than
96% of the 705 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. ABBV: 0.09 )
Ranked among companies with meaningful Equity to Asset only.
ABBV' s Equity to Asset Range Over the Past 10 Years
Min: 0.05  Med: 0.13 Max: 0.69
Current: 0.09
0.05
0.69
Interest Coverage 10.13
ABBV's Interest Coverage is ranked lower than
64% of the 464 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.69 vs. ABBV: 10.13 )
Ranked among companies with meaningful Interest Coverage only.
ABBV' s Interest Coverage Range Over the Past 10 Years
Min: 7.95  Med: 5027.47 Max: 9999.99
Current: 10.13
7.95
9999.99
F-Score: 7
Z-Score: 2.32
M-Score: -2.14
WACC vs ROIC
11.31%
26.37%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 34.18
ABBV's Operating margin (%) is ranked higher than
94% of the 711 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.72 vs. ABBV: 34.18 )
Ranked among companies with meaningful Operating margin (%) only.
ABBV' s Operating margin (%) Range Over the Past 10 Years
Min: 17.09  Med: 30.15 Max: 34.7
Current: 34.18
17.09
34.7
Net-margin (%) 23.03
ABBV's Net-margin (%) is ranked higher than
90% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.02 vs. ABBV: 23.03 )
Ranked among companies with meaningful Net-margin (%) only.
ABBV' s Net-margin (%) Range Over the Past 10 Years
Min: 8.89  Med: 24.35 Max: 32.62
Current: 23.03
8.89
32.62
ROE (%) 134.66
ABBV's ROE (%) is ranked higher than
100% of the 742 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.16 vs. ABBV: 134.66 )
Ranked among companies with meaningful ROE (%) only.
ABBV' s ROE (%) Range Over the Past 10 Years
Min: 24.85  Med: 56.91 Max: 105.11
Current: 134.66
24.85
105.11
ROA (%) 11.31
ABBV's ROA (%) is ranked higher than
82% of the 769 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.69 vs. ABBV: 11.31 )
Ranked among companies with meaningful ROA (%) only.
ABBV' s ROA (%) Range Over the Past 10 Years
Min: 6.25  Med: 16.89 Max: 39.54
Current: 11.31
6.25
39.54
ROC (Joel Greenblatt) (%) 250.14
ABBV's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 762 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.05 vs. ABBV: 250.14 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ABBV' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 74.13  Med: 142.15 Max: 170.07
Current: 250.14
74.13
170.07
Revenue Growth (3Y)(%) 3.90
ABBV's Revenue Growth (3Y)(%) is ranked lower than
56% of the 603 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. ABBV: 3.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ABBV' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 3.90 Max: 5.7
Current: 3.9
0
5.7
EBITDA Growth (3Y)(%) -10.50
ABBV's EBITDA Growth (3Y)(%) is ranked lower than
78% of the 550 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.20 vs. ABBV: -10.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ABBV' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -10.50 Max: 2.2
Current: -10.5
0
2.2
EPS Growth (3Y)(%) -20.30
ABBV's EPS Growth (3Y)(%) is ranked lower than
81% of the 505 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.20 vs. ABBV: -20.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ABBV' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -20.30 Max: -1
Current: -20.3
» ABBV's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-24)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

ABBV Guru Trades in Q2 2015

First Eagle Investment 678,300 sh (New)
Louis Moore Bacon 25,000 sh (New)
Steven Cohen 1,245,500 sh (+760.15%)
Larry Robbins 17,855,941 sh (+630.71%)
David Dreman 28,292 sh (+193.03%)
Scott Black 151,910 sh (+27.14%)
Pioneer Investments 2,701,617 sh (+14.08%)
Louis Moore Bacon 100,000 sh (unchged)
Robert Bruce 232,915 sh (unchged)
Jeff Auxier 19,171 sh (unchged)
Tom Russo 86,718 sh (unchged)
Westport Asset Management Sold Out
Manning & Napier Advisors, Inc Sold Out
Murray Stahl 32,060 sh (-0.01%)
Ken Fisher 1,006,679 sh (-0.40%)
Mairs and Power 268,776 sh (-1.19%)
Mario Gabelli 46,562 sh (-1.38%)
Dodge & Cox 34,255 sh (-2.28%)
Lee Ainslie 3,950 sh (-8.56%)
NWQ Managers 1,583,682 sh (-13.88%)
PRIMECAP Management 2,799,320 sh (-24.97%)
Paul Tudor Jones 6,500 sh (-35.45%)
Joel Greenblatt 33,605 sh (-93.95%)
Jim Simons 8,200 sh (-99.31%)
» More
Q3 2015

ABBV Guru Trades in Q3 2015

Jim Simons 2,933,756 sh (+35677.51%)
Paul Tudor Jones 49,480 sh (+661.23%)
Joel Greenblatt 73,037 sh (+117.34%)
First Eagle Investment 1,056,150 sh (+55.71%)
David Dreman 31,197 sh (+10.27%)
Murray Stahl 35,121 sh (+9.55%)
Jeff Auxier 20,272 sh (+5.74%)
Scott Black 154,855 sh (+1.94%)
Tom Russo 86,718 sh (unchged)
Robert Bruce 232,915 sh (unchged)
Lee Ainslie Sold Out
Louis Moore Bacon Sold Out
Steven Cohen Sold Out
Mairs and Power 266,936 sh (-0.68%)
Dodge & Cox 33,255 sh (-2.92%)
NWQ Managers 1,526,806 sh (-3.59%)
Mario Gabelli 43,930 sh (-5.65%)
Ken Fisher 927,959 sh (-7.82%)
Larry Robbins 16,170,903 sh (-9.44%)
PRIMECAP Management 2,511,945 sh (-10.27%)
Pioneer Investments 2,286,962 sh (-15.35%)
» More
Q4 2015

ABBV Guru Trades in Q4 2015

First Pacific Advisors 75,500 sh (New)
Louis Moore Bacon 36,243 sh (New)
John Paulson 139,700 sh (New)
Joel Greenblatt 204,171 sh (+179.54%)
Murray Stahl 36,019 sh (+2.56%)
Ken Fisher 935,104 sh (+0.77%)
Tom Russo 86,718 sh (unchged)
Dodge & Cox 33,255 sh (unchged)
Jeff Auxier 20,272 sh (unchged)
Robert Bruce 232,915 sh (unchged)
Samuel Isaly 1,225,000 sh (unchged)
First Eagle Investment Sold Out
Mairs and Power 266,811 sh (-0.05%)
Mario Gabelli 40,600 sh (-7.58%)
David Dreman 26,267 sh (-15.80%)
Larry Robbins 13,544,815 sh (-16.24%)
Paul Tudor Jones 32,925 sh (-33.46%)
Pioneer Investments 1,150,074 sh (-49.71%)
NWQ Managers 754,413 sh (-50.59%)
PRIMECAP Management 1,165,045 sh (-53.62%)
Scott Black 40,798 sh (-73.65%)
Jim Simons 582,756 sh (-80.14%)
» More
Q1 2016

ABBV Guru Trades in Q1 2016

Lee Ainslie 43,170 sh (New)
Joel Greenblatt 645,835 sh (+216.32%)
Jim Simons 1,563,056 sh (+168.22%)
David Dreman 30,542 sh (+16.28%)
Pioneer Investments 1,261,434 sh (+9.68%)
NWQ Managers 781,850 sh (+3.64%)
Scott Black 41,959 sh (+2.85%)
Jeff Auxier 20,572 sh (+1.48%)
Larry Robbins 13,686,588 sh (+1.05%)
Mairs and Power 268,191 sh (+0.52%)
Murray Stahl 36,154 sh (+0.37%)
Robert Bruce 232,915 sh (unchged)
Samuel Isaly 1,225,000 sh (unchged)
Louis Moore Bacon Sold Out
John Paulson Sold Out
Dodge & Cox 33,232 sh (-0.07%)
PRIMECAP Management 1,022,845 sh (-12.21%)
Mario Gabelli 35,460 sh (-12.66%)
Ken Fisher 743,284 sh (-20.51%)
First Pacific Advisors 56,050 sh (-25.76%)
Tom Russo 21,718 sh (-74.96%)
Paul Tudor Jones 4,100 sh (-87.55%)
» More
» Details

Insider Trades

Latest Guru Trades with ABBV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:SNY, OTCPK:GLAXF, NYSE:LLY, OTCPK:BAYRY, NYSE:BMY, NYSE:AZN, NYSE:MRK, OTCPK:ALPMY, OTCPK:OTSKF, OTCPK:OPHLY, OTCPK:CHGCF, OTCPK:DSNKY, NYSE:NVS, OTCPK:KYKOF, OTCPK:SNPHY, OTCPK:CHJTF, OTCPK:PTKFF, NAS:ZSPH, NAS:GWPH, AMEX:TXMD » details
Traded in other countries:ABBV34.Brazil, ABBV.France, 4AB.Germany, ABBV.Mexico, ABBV.Switzerland, 0QCV.UK,
AbbVie Inc is a research-based biopharmaceutical company. Its products are used to treat diseases including rheumatoid arthritis, psoriasis, Crohn's disease, HIV, cystic fibrosis complications.

AbbVie Inc is a research-based biopharmaceutical company incorporated in Delaware on April 10, 2012. The Company is engaged in the discovery, development, manufacture and sale of a broad line of pharmaceutical products. It develops and markets therapies that address some of the world's complex and serious diseases. It products are focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. It also has a pipeline of new medicines, including more than 50 compounds or indications in clinical development across such important medical specialties as immunology, virology/liver disease, oncology, neurological diseases and women's health. The Company's products offering includes HUMIRA, IMBRUVICA, VIEKIRA, Creon, Synagis, Lupron, Synthroid, Kaletra, AndroGel, Sevoflurane, Duodopa, Dyslipidemia products, and other products. The Company's products are sold directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from AbbVie-owned distribution centers and public warehouses. The Company faces competition from other research-based pharmaceuticals and biotechnology companies that discover, manufacture, market, and sell proprietary pharmaceutical products and biologics. The manufacture, marketing, sale, promotion, and distribution of AbbVie's products are subject to comprehensive government regulation.

Top Ranked Articles about AbbVie Inc

Merck & Co. Versus AbbVie: Who Is the Winner and Who Is the Loser? The question that needs to be asked about AbbVie's demise is: What caused the earnings decline in the last five years after it went public?
Merck & Co. (NYSE: MRK) and AbbVie Inc. (NYSE: ABBV) are two very different companies and face very different situations when it comes to earnings and growth, not to mention one is significantly older than the other. From 2009 to 2010, Merck's earnings fell by 14 times what they previously were but have made a comeback and have leveled out while AbbVie has only been public since 2013 and in its short history as a public has seen its earnings plunge by 20.31% annually. Merck's earnings have stayed consistent since its earnings recovered from 26 cents in December 2010 to $3.74 currently. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 18.05
ABBV's P/E(ttm) is ranked higher than
68% of the 546 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.68 vs. ABBV: 18.05 )
Ranked among companies with meaningful P/E(ttm) only.
ABBV' s P/E(ttm) Range Over the Past 10 Years
Min: 9.85  Med: 19.91 Max: 63.37
Current: 18.05
9.85
63.37
Forward P/E 12.55
ABBV's Forward P/E is ranked higher than
68% of the 82 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.75 vs. ABBV: 12.55 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 18.00
ABBV's PE(NRI) is ranked higher than
69% of the 538 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.96 vs. ABBV: 18.00 )
Ranked among companies with meaningful PE(NRI) only.
ABBV' s PE(NRI) Range Over the Past 10 Years
Min: 9.85  Med: 19.91 Max: 63.95
Current: 18
9.85
63.95
Price/Owner Earnings (ttm) 14.67
ABBV's Price/Owner Earnings (ttm) is ranked higher than
81% of the 268 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.84 vs. ABBV: 14.67 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ABBV' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 13.74  Med: 15.77 Max: 61.16
Current: 14.67
13.74
61.16
P/B 20.84
ABBV's P/B is ranked lower than
98% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.88 vs. ABBV: 20.84 )
Ranked among companies with meaningful P/B only.
ABBV' s P/B Range Over the Past 10 Years
Min: 15.47  Med: 20.27 Max: 77.07
Current: 20.84
15.47
77.07
P/S 4.14
ABBV's P/S is ranked lower than
63% of the 715 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.66 vs. ABBV: 4.14 )
Ranked among companies with meaningful P/S only.
ABBV' s P/S Range Over the Past 10 Years
Min: 2.83  Med: 4.32 Max: 5.67
Current: 4.14
2.83
5.67
PFCF 12.98
ABBV's PFCF is ranked higher than
77% of the 197 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.78 vs. ABBV: 12.98 )
Ranked among companies with meaningful PFCF only.
ABBV' s PFCF Range Over the Past 10 Years
Min: 8.65  Med: 14.56 Max: 38.18
Current: 12.98
8.65
38.18
POCF 12.13
ABBV's POCF is ranked higher than
68% of the 265 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.60 vs. ABBV: 12.13 )
Ranked among companies with meaningful POCF only.
ABBV' s POCF Range Over the Past 10 Years
Min: 8.2  Med: 13.42 Max: 31.6
Current: 12.13
8.2
31.6
EV-to-EBIT 15.10
ABBV's EV-to-EBIT is ranked higher than
65% of the 537 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.24 vs. ABBV: 15.10 )
Ranked among companies with meaningful EV-to-EBIT only.
ABBV' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.2  Med: 15.60 Max: 41
Current: 15.1
10.2
41
EV-to-EBITDA 13.47
ABBV's EV-to-EBITDA is ranked higher than
61% of the 568 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.55 vs. ABBV: 13.47 )
Ranked among companies with meaningful EV-to-EBITDA only.
ABBV' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.6  Med: 13.70 Max: 33.1
Current: 13.47
8.6
33.1
Current Ratio 1.56
ABBV's Current Ratio is ranked lower than
71% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.42 vs. ABBV: 1.56 )
Ranked among companies with meaningful Current Ratio only.
ABBV' s Current Ratio Range Over the Past 10 Years
Min: 1.22  Med: 2.04 Max: 2.82
Current: 1.56
1.22
2.82
Quick Ratio 1.39
ABBV's Quick Ratio is ranked lower than
63% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.78 vs. ABBV: 1.39 )
Ranked among companies with meaningful Quick Ratio only.
ABBV' s Quick Ratio Range Over the Past 10 Years
Min: 1.06  Med: 1.84 Max: 2.65
Current: 1.39
1.06
2.65
Days Inventory 118.44
ABBV's Days Inventory is ranked lower than
52% of the 667 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.06 vs. ABBV: 118.44 )
Ranked among companies with meaningful Days Inventory only.
ABBV' s Days Inventory Range Over the Past 10 Years
Min: 35.55  Med: 79.47 Max: 93.77
Current: 118.44
35.55
93.77
Days Sales Outstanding 72.96
ABBV's Days Sales Outstanding is ranked higher than
51% of the 619 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.75 vs. ABBV: 72.96 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABBV' s Days Sales Outstanding Range Over the Past 10 Years
Min: 71.53  Med: 78.73 Max: 93.3
Current: 72.96
71.53
93.3
Days Payable 118.31
ABBV's Days Payable is ranked higher than
75% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.86 vs. ABBV: 118.31 )
Ranked among companies with meaningful Days Payable only.
ABBV' s Days Payable Range Over the Past 10 Years
Min: 30.33  Med: 153.73 Max: 185.97
Current: 118.31
30.33
185.97

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.61
ABBV's Dividend Yield is ranked higher than
84% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.58 vs. ABBV: 3.61 )
Ranked among companies with meaningful Dividend Yield only.
ABBV' s Dividend Yield Range Over the Past 10 Years
Min: 0.85  Med: 2.93 Max: 3.84
Current: 3.61
0.85
3.84
Dividend Payout 0.63
ABBV's Dividend Payout is ranked lower than
78% of the 372 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. ABBV: 0.63 )
Ranked among companies with meaningful Dividend Payout only.
ABBV' s Dividend Payout Range Over the Past 10 Years
Min: 0.55  Med: 0.66 Max: 1.36
Current: 0.63
0.55
1.36
Forward Dividend Yield 3.81
ABBV's Forward Dividend Yield is ranked higher than
84% of the 564 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.69 vs. ABBV: 3.81 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 3.61
ABBV's Yield on cost (5-Year) is ranked higher than
69% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.11 vs. ABBV: 3.61 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ABBV' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.85  Med: 2.93 Max: 3.84
Current: 3.61
0.85
3.84
3-Year Average Share Buyback Ratio -0.30
ABBV's 3-Year Average Share Buyback Ratio is ranked higher than
75% of the 427 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.60 vs. ABBV: -0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ABBV' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.3  Med: -0.20 Max: 0
Current: -0.3
-0.3
0

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.96
ABBV's Price/Median PS Value is ranked higher than
61% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.09 vs. ABBV: 0.96 )
Ranked among companies with meaningful Price/Median PS Value only.
ABBV' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.68  Med: 0.99 Max: 1.22
Current: 0.96
0.68
1.22
Earnings Yield (Greenblatt) (%) 6.68
ABBV's Earnings Yield (Greenblatt) (%) is ranked higher than
75% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. ABBV: 6.68 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ABBV' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.4  Med: 6.40 Max: 9.8
Current: 6.68
2.4
9.8

More Statistics

Revenue (TTM) (Mil) $23,777
EPS (TTM) $ 3.32
Beta1.47
Short Percentage of Float4.84%
52-Week Range $45.45 - 71.60
Shares Outstanding (Mil)1,617.36

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 25,132 27,493 29,220
EPS ($) 4.75 5.60 6.40
EPS w/o NRI ($) 4.75 5.60 6.40
EPS Growth Rate
(3Y to 5Y Estimate)
1.85%
» More Articles for NYSE:ABBV

Headlines

Articles On GuruFocus.com
5 Attractive Biotechnology Stocks for Healthy Long-term Returns Jun 10 2016 
Weekly CEO Sells Highlight Jun 06 2016 
Wall Street Estimates and Biopharma Value Investing Jun 02 2016 
Dividend and Value Opportunities in the Large-Cap Pharmaceutical Space Apr 05 2016 
A Cheap Dividend Aristocrat Yielding Over 4% Mar 02 2016 
John Paulson Bulks Up Health Care Bet Feb 17 2016 
Gilead, Johnson & Johnson or Roche? Feb 11 2016 
Glenview's Larry Robbins Lowers Drug Manufacturers, Raises Providers Nov 20 2015 
Health Care Investor Larry Robbins Lowers Drug Manufacturers, Raises Providers Nov 20 2015 
Merck & Co. Versus AbbVie: Who Is the Winner and Who Is the Loser? Nov 12 2015 

More From Other Websites
2 Key FDA Actions On Potential Blockbuster Drugs Next Week Jun 24 2016
AbbVie, Inc. : ABBV-US: Dividend Analysis : July 15th, 2016 (record date) : By the numbers : June... Jun 24 2016
CORRECTED (OFFICIAL)-Novartis aims to nearly triple biosimilar drugs on market by 2020 Jun 20 2016
AbbVie Teams Up with Leading Nonprofit Organizations to Give Back to Underserved Local Communities Jun 20 2016
Novartis aims to nearly triple biosimilar drugs on market by 2020 Jun 19 2016
6 Companies That Destroyed Shareholders Last Week Jun 19 2016
AbbVie Declares Quarterly Dividend Jun 16 2016
AbbVie Declares Quarterly Dividend Jun 16 2016
AbbVie Scholarship Programs Recognize Exceptional Students Living with Chronic Inflammatory Diseases Jun 16 2016
[$$] Infinity Pharmaceuticals' Disappointing Data Jun 16 2016
One Reason Why AbbVie (ABBV) Stock Closed Up Today Jun 15 2016
Infinity Pharmaceuticals Faces Downgrades as Drug Results Disappoint Jun 15 2016
AbbVie: Low Expectations, Cheap Valuation, What's Not to Love? Jun 15 2016
6 Biopharma Movers Making a Run on Wednesday Jun 15 2016
Infinity (INFI) at 52-Week Low on Disappointing Duvelisib Data Jun 15 2016
Why Infinity Pharmaceuticals Crashed Jun 14 2016
Agios Upgraded As Anemia Drug Data Soothes Safety Concerns Jun 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)